Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: tommysdad who wrote (2878)	6/29/2013 12:11:31 AM
From: Biomaven	Respond to of 3202

I do recall the Sepracor antihistamine drug that ultimately got derailed because of a long-lasting minor metabolite. But there I think there was some issue of accumulation in tissue. And that that is a good thing. Because . . . I lose the thread at that point. Well they claim it potentially allows QD dosing, which would indeed be a good thing. I believe there are at least a few dozen approved drugs (not designed as pro-drugs) where the active metabolite turns out to have the dominant activity - e.g., risperidone and tramadol. There are others where the active metabolite contributes to the activity (like Prozac) but isn't dominant. So this may not be elegant, but not sure how much of a problem it will actually be for them (assuming, as you hypothesize, that the tox species make the same metabolite in similar amounts). Peter